APOE and Alzheimer disease: LXR agonist GW3965 attenuates neuroinflammation and regulates brain cholesterol metabolism in AD by increasing ApoE expression, inhibiting astrogliosis, restoration of microvascular morphology, and inhibiting accumulation of Aβ in the blood vessels [71].